But the authors of the study and an accompanying comment stress that the potential risks of long term aspirin use at this dose and the availability of alternative prevention strategies mean that widespread use of aspirin for cancer prevention cannot be recommended in the general population.
However, the benefits are likely to outweigh the risks in individuals at increased risk of colon cancer. The findings are also likely to influence the choice of antiplatelet drug in patients who require long-term treatment because of vascular disease.
The study was conducted by Professor Peter Rothwell, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford, UK and colleagues. In collaboration with the original investigators (Sir Richard Doll, Sir Richard Peto and Charles Warlow), they determined the delayed effect of aspirin by following-up patients from two large randomised trials of aspirin performed in the late 1970s and early 80s - the British Doctors’ Aspirin Trial and the UK-TIA Aspirin Trial.
The researchers were particularly interested in long term follow-up due to the likely time delay in any effect of aspirin on colorectal cancer. Adenomas (the pre-cancerous growths that aspirin is thought to reduce) take at least 10 years to develop into cancers. The study showed that use of Aspirin for five years reduced the subsequent incidence of colorectal cancer by 37% overall, and by 74% during the period 10-15 years after treatment was started.
In an accompanying analysis of observational studies, the risk of colorectal cancer also appeared to be reduced by between 50-70% in patients taking medium-high doses of aspirin for 10 years or more. This analysis also showed that the effects of aspirin were consistent regardless of age, sex, race or country of origin of patients studied (all of which affect the general rate of colorectal cancer) and that the effect was also seen in individuals with a family history of colorectal cancer in a first degree family relative (which increases lifetime risk of an individual acquiring the disease by two to four times).
The authors conclude: “Use of 300mg or more of aspirin a day for about five years is effective in primary prevention of colorectal cancer, with a latency of about 10 years, which is consistent with findings from observational studies.
“Long-term follow up is required from other randomised trials to establish the effects of lower or less frequent doses of aspirin.”
In an accompanying comment, Dr Andrew Chan, Gastrointestinal Unit, Massachusetts General Hospital, Boston, USA, says: “Rothwell and colleagues’ results, when viewed in the context of the preponderance of laboratory studies, epidemiological data, and adenoma recurrence trials, do provide convincing evidence that aspirin, at biologically relevant doses, can reduce the incidence of colorectal cancer.
“However, with the concerns about the potential risks of long-term aspirin use and the availability of alternative prevention strategies (e.g. screening), these findings are not sufficient to warrant a recommendation for the general population to use aspirin for cancer prevention.”
Tony Kirby | alfa
Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Information Technology
20.10.2017 | Materials Sciences
20.10.2017 | Interdisciplinary Research